Mesoblast (ASX:MSB) Tariff Resilience Score: 6/10 (As of Jun. 29, 2026)


ASX:MSB Mesoblast Ltd ASX:MSB
46 GF Score
Price A$1.95
! 4 Warning Signs
View Full Analysis

What is Mesoblast Tariff Resilience Score?

Mesoblast ASX:MSB +3.45% 46 Tariff Resilience Score is 6 as of Jun. 29, 2026. GuruFocus rates ASX:MSB with a GF Score™ of 46/100. The stock has 4 warning signs investors should review. Among 1,375 Biotechnology companies, Mesoblast ranks better than 76% on this metric.

Mesoblast has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Mesoblast has Mesoblast has a global supply chain with manufacturing in the US and Australia. Its primary market is the US, reducing exposure to tariffs. However, reliance on international suppliers for raw materials poses some risk. Historical tariff impacts have been minimal, and the company can leverage alternative suppliers.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Mesoblast might have Average Resilient.

Mesoblast  (ASX:MSB) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Mesoblast Tariff Resilience Score Related Terms

ASX:MSB vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Mesoblast's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mesoblast Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mesoblast's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Mesoblast's Tariff Resilience Score falls into.


ASX:MSB
46GF Score
Mesoblast Ltd ASX:MSB
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Mesoblast (ASX:MSB) has a Tariff Resilience Score of 6 as of Jun. 29, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Mesoblast ranks #330 out of 1375 companies in the Biotechnology industry, placing it in the top 24%.
Is Mesoblast's Tariff Resilience Score too high?
Mesoblast's current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Mesoblast's value of 6 is 50% above this industry median. Based on the distribution chart, Mesoblast ranks #330 out of 1375 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Mesoblast has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Mesoblast's Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Mesoblast ranks #330 out of 1375 companies for Tariff Resilience Score. This places Mesoblast in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Mesoblast's value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,375 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mesoblast's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mesoblast's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mesoblast stock overvalued right now?
Mesoblast (ASX:MSB) has a current Tariff Resilience Score of 6. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Mesoblast's overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Mesoblast (ASX:MSB), the current Tariff Resilience Score is 6 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mesoblast Business Description

Address 55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
46GF Score

Get the complete analysis for ASX:MSB

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.95
Price